After selling portions of its money losing online pharmaceutical division, Cybear Group, Andrx Group is likely looking to divest the remainder of that unit’s assets. Although the $1.3 billion marked cap generic drug maker and a few analysts believe the business of marketing drugs online will ultimately serve to cut down the glutted ranks of drug salesmen, at this point, Andrx would rather focus on its core drug-delivery business, they said.
To read the entire story, you must be logged in.
Please log in now or register with us.
